First-Line Japan Alecensa Trial Stopped Early On Benefits
This article was originally published in Scrip
A Japanese Phase III trial investigating the first-line use of Chugai Pharmaceutical Co. Ltd's alectinib in lung cancer has been halted early following better than expected positive results, boding well for the ALK inhibitor in this important setting.
You may also be interested in...
The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.
Novartis’s anticancer Zykadia is catching up its rival, Pfizer’s Xalkori, by showing a benefit when used first line in the Phase III ASCEND-4 study in NSCLC, but must still look over its shoulder at Roche’s Alecensa.
Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.